SA PRO
Free Account
Gilead Sciences, Inc.GILDNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 76% recommend buying.

Consensus Rating
Buy
25 analysts·High coverage
76%
Rating Distribution
Strong Buy
00%
Buy
1976%
Hold
624%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Current price is 8% above analyst consensus — modest downside expected.

Bear Case
$105.00
-31%
Consensus
$139.83
-8%
Bull Case
$155.00
+2%
Price Range25 analysts
Low
Consensus
High
$105.00
$155.00
Current Target
Current Price
$151.68
Above Target
$11.85

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$8.79(18 analysts)
P/E23x
Current: 23.4x
Actual
Estimate
Range (Low–High)
Stock Alarm Pro
Forward Growth Estimates (YoY)
FY2027
Rev+4.89%
EPS+7.39%
FY2028
Rev+5.29%
EPS+7.68%
FY2029
Rev+4.09%
EPS+8.73%

Earnings Surprises

Beat rate:75%(9/12 quarters)
Avg surprise:+7.9%
Beat
Miss
Inline
Estimate
Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 27, 2026Truist Financial
Gilead price target raised to $145 from $140 at Truist
Target:$145.00
+4.1%from $139.23
Jan 26, 2026BMO Capital
Gilead Sciences (GILD) PT Raised to $150 at BMO Capital
Target:$150.00
+9.5%from $137.01
Jan 26, 2026UBS
Gilead price target raised to $155 from $145 at UBS
Target:$155.00
+13.8%from $136.16
Jan 13, 2026Morgan Stanley
Gilead price target lowered to $150 from $151 at Morgan Stanley
Target:$150.00
+22.7%from $122.25
Jan 7, 2026UBS
Gilead assumed with Buy from Neutral at UBS
Target:$145.00
+19.5%from $121.36
Dec 29, 2025Bernstein
Bernstein Reiterates Outperform Rating on Gilead Sciences (GILD)
Target:$135.00
+8.4%from $124.56
Dec 15, 2025Wolfe Research
Gilead Sciences (GILD) PT Raised to $150 at Wolfe Research
Target:$150.00
+24.6%from $120.41
Dec 12, 2025Morgan Stanley
Gilead price target raised to $151 from $147 at Morgan Stanley
Target:$151.00
+22.6%from $123.21
Dec 10, 2025HSBC
Gilead price target raised to $133 from $110 at HSBC
Target:$133.00
+11.4%from $119.36
Nov 25, 2025BMO Capital
BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
Target:$135.00
+5.8%from $127.57
Nov 24, 2025Truist Financial
Gilead assumed with a Buy at Truist
Target:$140.00
+9.5%from $127.91
Nov 20, 2025Mizuho Securities
Gilead price target raised to $140 from $131 at Mizuho
Target:$140.00
+12.0%from $124.99
Oct 31, 2025Morgan Stanley
Gilead price target raised to $147 from $143 at Morgan Stanley
Target:$147.00
+24.0%from $118.52
Oct 31, 2025RBC Capital
Gilead price target raised to $105 from $100 at RBC Capital
Target:$105.00
-11.3%from $118.44
Oct 31, 2025Wells Fargo
Gilead price target raised to $145 from $140 at Wells Fargo
Target:$145.00
+22.4%from $118.44
Oct 9, 2025Cantor Fitzgerald
Gilead price target raised to $135 from $129 at Cantor Fitzgerald
Target:$135.00
+14.2%from $118.25
Oct 6, 2025Wells Fargo
Wells says Biktarvy patent settlement 'big deal' for Gilead at, $6-$12 upside
Target:$140.00
+24.2%from $112.69
Aug 11, 2025Deutsche Bank
Gilead price target raised to $135 from $120 at Deutsche Bank
Target:$135.00
+13.6%from $118.83
Aug 8, 2025Robert W. Baird
Gilead price target raised to $108 from $100 at Baird
Target:$108.00
-9.6%from $119.41
Aug 8, 2025Morgan Stanley
Gilead price target raised to $143 from $135 at Morgan Stanley
Target:$143.00
+19.8%from $119.41
Jul 14, 2025Leerink Partners
Gilead price target raised to $114 from $105 at Leerink
Target:$114.00
+1.7%from $112.09
Jun 18, 2025Morgan Stanley
Morgan Stanley says FDA approval of Yeztugo 'an expected positive' for Gilead
Target:$135.00
+25.0%from $108.00
Apr 22, 2025Cantor Fitzgerald
Gilead assumed at Overweight from Neutral at Cantor Fitzgerald
Target:$125.00
+18.5%from $105.51
Mar 11, 2025Morgan Stanley
Gilead price target raised to $130 from $123 at Morgan Stanley
Target:$130.00
+13.6%from $114.43
Mar 5, 2025Johnson Rice
Gilead price target raised to $126 from $116 at BofA
Target:$126.00
+9.1%from $115.44

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance